Bevacizumab Effect on Blood Velocity

This study has been completed.
Sponsor:
Information provided by:
Optical Imaging, Ltd.
ClinicalTrials.gov Identifier:
NCT01298440
First received: February 16, 2011
Last updated: NA
Last verified: February 2011
History: No changes posted
  Purpose
Retinal blood flow velocity is affected by Bevacizump intravitreal injection. This effect is correlated to treatment success.

Condition
Choroidal Neovascularization

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: The Effect of Intravitreal Bevacizumab (Avastin) Injection on Retinal Blood-Flow Velocity in Patients With Choroidal Neovascularization

Resource links provided by NLM:


Further study details as provided by Optical Imaging, Ltd.:

Primary Outcome Measures:
  • Blood flow velocity change [ Time Frame: 1 day following injection ] [ Designated as safety issue: No ]

Enrollment: 12
Study Start Date: January 2008
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Detailed Description:
The purpose of the study was to carry out a pilot study on the short-term effect of intravitreal Bevacizumab (Avastin) injection on retinal blood-flow velocity and test whether the short-term haemodynamic changes could predict the longer term clinical result of the treatment.
  Eligibility

Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with choroidal neovascularization (CNV)
Criteria

Inclusion Criteria:

  • Patients with CNV receiving Bevacizumab intravitreal injection

Exclusion Criteria:

  • Candidates in whom the retina could not be seen clearly because of media opacity or a poorly dilating pupil
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01298440

Locations
Israel
Tel aviv sourasky medical center
Tel aviv, Israel, 64239
Sponsors and Collaborators
Optical Imaging, Ltd.
Investigators
Principal Investigator: Adiel Barak, MD Tel aviv university Sackler school of medicine
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Optical Imaging, Ltd
ClinicalTrials.gov Identifier: NCT01298440     History of Changes
Other Study ID Numbers: AvastinRFI 
Study First Received: February 16, 2011
Last Updated: February 16, 2011
Health Authority: Israel: Ministry of Health

Additional relevant MeSH terms:
Neovascularization, Pathologic
Choroidal Neovascularization
Metaplasia
Pathologic Processes
Choroid Diseases
Uveal Diseases
Eye Diseases
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents

ClinicalTrials.gov processed this record on July 28, 2016